Cost-effectiveness of antiplatelet agents in secondary stroke prevention: The limits of certainty

Value in Health

Volumn 8, Issue 5, 2005, Pages 572-580

  Matchar, David B ^a,b,c   Samsa, Gregory P ^a,d   Liu, Suping ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet; Bootstrapping; Cost effectiveness acceptability curves; Cost effectiveness modeling; Secondary stroke prevention; Simulation analysis

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; DIPYRIDAMOLE; DRUG DERIVATIVE; TICLOPIDINE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SENSITIVITY ANALYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEART INFARCTION; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK; STATISTICAL MODEL; UNCERTAINTY;

AGED; ASPIRIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIPYRIDAMOLE; FEMALE; HEALTH CARE COSTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MODELS, ECONOMETRIC; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK; TICLOPIDINE; UNCERTAINTY;

EID: 27744576942     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.00050.x     Document Type: Article

References (19)

1. Donnan GA, Davis SM, Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002;33:2137-8.
2. Diener HC. Aspirin therapy should be first-line treatment in secondary prevention of stroke-against. Stroke 2002;33:2138-9.
3. Donnan GA. Aspirin therapy should be first line: probably, but watch this space. Stroke 2002;33: 2139-40.
4. Matchar DB, Samsa GP, Matthews JR, et al. The Stroke Prevention Policy Model (SPPM): linking evidence and clinical decisions. Ann Intern Med 1997;127:704-11.
5. Parmigiani G, Ancukiewicz M, Matchar DB. Decision Models in Clinical Recommendations Development: the Stroke Prevention Policy Model. In: Berry DA, Stangl DK, eds. Bayesian Biostatistics (1st ed.). New York: Marcel Dekker, 1996.
6. Samsa GP, Matchar DB. Have randomized trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001;32:669-74.
7. Rankin J. Cerebral vascular accidents in patients over age 60. Scott Med J 1957;2:200-15.
8. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-18.
9. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1966;143:1-13.
10. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischeaemic events (CAPRIE). Lancet 1996;348:1329-39.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
12. Matchar DB, McCrory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med 1994;121:41-53.
13. Walgreens. Drug Information & Prices. Available from: http://www.walgreens.com/library/finddrug/ druginfosearch.jhtml [Accessed August 10, 2005].
14. Pharmacy Benefits Management Strategic Health Care Group. Drug & Pharmaceutical Prices. Available from: http://www.vapbm.org/PBM/prices.htm [Accessed August 8, 2005].
15. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9:623-30.
16. Sarasin FP, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Int Med 2000;160:2773-8.
17. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin Ther 2000;22:362-70.
18. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004;116:797-806.
19. Kassirer JP, Pauker SG. The toss-up. N Engl J Med 1981;305:1467-9.